These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 31395128)

  • 1. Homeostatic Chemokines and Prognosis in Patients With Acute Coronary Syndromes.
    Caidahl K; Hartford M; Ravn-Fischer A; Lorentzen E; Yndestad A; Karlsson T; Aukrust P; Ueland T
    J Am Coll Cardiol; 2019 Aug; 74(6):774-782. PubMed ID: 31395128
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plasma homeostatic chemokines CCL19 and CCL21 and the prognosis of ischemic stroke in two Chinese prospective cohorts.
    Che B; Zhong C; Du J; Miao M; Shi M; Peng Y; Yang P; Guo D; Chen J; Wang A; Xu T; Zhang Y; He J
    Eur J Neurol; 2023 Oct; 30(10):3149-3160. PubMed ID: 37399099
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum neutrophil gelatinase-associated lipocalin (NGAL) concentration is independently associated with mortality in patients with acute coronary syndrome.
    Nymo SH; Hartford M; Ueland T; Yndestad A; Lorentzen E; Truvé K; Karlsson T; Ravn-Fischer A; Aukrust P; Caidahl K
    Int J Cardiol; 2018 Jul; 262():79-84. PubMed ID: 29622507
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Improved risk stratification of patients with acute coronary syndromes using a combination of hsTnT, NT-proBNP and hsCRP with the GRACE score.
    Klingenberg R; Aghlmandi S; Räber L; Gencer B; Nanchen D; Heg D; Carballo S; Rodondi N; Mach F; Windecker S; Jüni P; von Eckardstein A; Matter CM; Lüscher TF
    Eur Heart J Acute Cardiovasc Care; 2018 Mar; 7(2):129-138. PubMed ID: 28029055
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The homeostatic chemokine CCL21 predicts mortality and may play a pathogenic role in heart failure.
    Yndestad A; Finsen AV; Ueland T; Husberg C; Dahl CP; Øie E; Vinge LE; Sjaastad I; Sandanger Ø; Ranheim T; Dickstein K; Kjekshus J; Damås JK; Fiane AE; Hilfiker-Kleiner D; Lipp M; Gullestad L; Christensen G; Aukrust P
    PLoS One; 2012; 7(3):e33038. PubMed ID: 22427939
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increased expression of the homeostatic chemokines CCL19 and CCL21 in clinical and experimental Rickettsia conorii infection.
    Astrup E; Ranheim T; Damås JK; Davì G; Santilli F; Jensenius M; Vitale G; Aukrust P; Olano JP; Otterdal K
    BMC Infect Dis; 2014 Feb; 14():70. PubMed ID: 24507453
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reevaluation of cardiac risk scores and multiple biomarkers for the prediction of first major cardiovascular events and death in the drug-eluting stent era.
    Onda T; Inoue K; Suwa S; Nishizaki Y; Kasai T; Kimura Y; Fukuda K; Okai I; Fujiwara Y; Matsuoka J; Sumiyoshi M; Daida H
    Int J Cardiol; 2016 Sep; 219():180-5. PubMed ID: 27327504
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased CCL19 and CCL21 levels promote fibroblast ossification in ankylosing spondylitis hip ligament tissue.
    Qin Y; He LD; Sheng ZJ; Yong MM; Sheng YS; Wei Dong X; Wen Wen T; Ming ZY
    BMC Musculoskelet Disord; 2014 Sep; 15():316. PubMed ID: 25260647
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CCL21 in Acute Coronary Syndromes: Biomarker of the 21st Century?
    Silvestre JS
    J Am Coll Cardiol; 2019 Aug; 74(6):783-785. PubMed ID: 31395129
    [No Abstract]   [Full Text] [Related]  

  • 10. Contribution of homeostatic chemokines CCL19 and CCL21 and their receptor CCR7 to coronary artery disease.
    Cai W; Tao J; Zhang X; Tian X; Liu T; Feng X; Bai J; Yan C; Han Y
    Arterioscler Thromb Vasc Biol; 2014 Sep; 34(9):1933-41. PubMed ID: 24990231
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multimarker risk assessment including osteoprotegerin and CXCL16 in acute coronary syndromes.
    Jansson AM; Hartford M; Omland T; Karlsson T; Lindmarker P; Herlitz J; Ueland T; Aukrust P; Caidahl K
    Arterioscler Thromb Vasc Biol; 2012 Dec; 32(12):3041-9. PubMed ID: 23023373
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Soluble CXCL16 predicts long-term mortality in acute coronary syndromes.
    Jansson AM; Aukrust P; Ueland T; Smith C; Omland T; Hartford M; Caidahl K
    Circulation; 2009 Jun; 119(25):3181-8. PubMed ID: 19528340
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enhanced expression of the homeostatic chemokines CCL19 and CCL21 in clinical and experimental atherosclerosis: possible pathogenic role in plaque destabilization.
    Damås JK; Smith C; Øie E; Fevang B; Halvorsen B; Waehre T; Boullier A; Breland U; Yndestad A; Ovchinnikova O; Robertson AK; Sandberg WJ; Kjekshus J; Taskén K; Frøland SS; Gullestad L; Hansson GK; Quehenberger O; Aukrust P
    Arterioscler Thromb Vasc Biol; 2007 Mar; 27(3):614-20. PubMed ID: 17170367
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term prognostic utility of pentraxin 3 and D-dimer as compared to high-sensitivity C-reactive protein and B-type natriuretic peptide in suspected acute coronary syndrome.
    Mjelva ØR; Pönitz V; Brügger-Andersen T; Grundt H; Staines H; Nilsen DW
    Eur J Prev Cardiol; 2016 Jul; 23(11):1130-40. PubMed ID: 26635361
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Plasma levels of CCL21, but not CCL19, independently predict future coronary events in a prospective population-based cohort.
    Katra P; Hennings V; Nilsson J; Engström G; Engelbertsen D; Bengtsson E; Björkbacka H
    Atherosclerosis; 2023 Feb; 366():1-7. PubMed ID: 36652748
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictive value of NT-proBNP for 30-day mortality in patients with non-ST-elevation acute coronary syndromes: a comparison with the GRACE and TIMI risk scores.
    Schellings DA; Adiyaman A; Dambrink JE; Gosselink AM; Kedhi E; Roolvink V; Ottervanger JP; Van't Hof AW
    Vasc Health Risk Manag; 2016; 12():471-476. PubMed ID: 27920547
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Usefulness of Beta2-Microglobulin as a Predictor of All-Cause and Nonculprit Lesion-Related Cardiovascular Events in Acute Coronary Syndromes (from the PROSPECT Study).
    Möckel M; Muller R; Searle J; Slagman A; De Bruyne B; Serruys P; Weisz G; Xu K; Holert F; Müller C; Maehara A; Stone GW
    Am J Cardiol; 2015 Oct; 116(7):1034-40. PubMed ID: 26254706
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Relationship between plasma N-terminal pro-brain natriuretic peptide and GRACE risk stratification in non-ST-segment elevation acute coronary syndrome].
    Liu WX; Zhao H
    Zhonghua Xin Xue Guan Bing Za Zhi; 2012 May; 40(5):373-7. PubMed ID: 22883085
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The soluble receptor for advanced glycation end-products (sRAGE) has a dual phase-dependent association with residual cardiovascular risk after an acute coronary event.
    Grauen Larsen H; Yndigegn T; Marinkovic G; Grufman H; Mares R; Nilsson J; Goncalves I; Schiopu A
    Atherosclerosis; 2019 Aug; 287():16-23. PubMed ID: 31181415
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment and outcomes of patients with suspected acute coronary syndromes in relation to initial diagnostic impressions (insights from the Canadian Global Registry of Acute Coronary Events [GRACE] and Canadian Registry of Acute Coronary Events [CANRACE]).
    Bajaj RR; Goodman SG; Yan RT; Bagnall AJ; Gyenes G; Welsh RC; Eagle KA; Brieger D; Ramanathan K; Grondin FR; Yan AT;
    Am J Cardiol; 2013 Jan; 111(2):202-7. PubMed ID: 23122889
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.